Emerging Roles of ADAM and ADAMTS Metalloproteinases in Cancer

[en] A disintegrin and metalloproteinases (ADAMs) are a recently discovered family of proteins that share the metalloproteinase domain with matrix metalloproteinases (MMPs). Among this family, structural features distinguish the membrane-anchored ADAMs and the secreted ADAMs with thrombospondin motifs referred to as ADAMTSs. By acting on a large panel of membrane-associated and extracellular substrates, they control several cell functions such as adhesion, fusion, migration and proliferation. The current review addresses the contribution of these proteinases in the positive and negative regulation of cancer progression as mainly mediated by the regulation of growth factor activities and integrin functions.

Research center :

Giga-Cancer - ULiège

Disciplines :

Biochemistry, biophysics & molecular biology

Author, co-author :

Rocks, Natacha ; Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement

Paulissen, Geneviève ; Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement

El Hour, Mehdi ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire appliquée à l'homme

Quesada Calvo, Florence ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques

Crahay, Céline

Guéders, Maud ; Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement

Foidart, Jean-Michel ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique

Noël, Agnès ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire appliquée à l'homme

Cataldo, Didier ; Université de Liège - ULiège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement - Département des sciences biomédicales et précliniques

Language :

English

Title :

Emerging Roles of ADAM and ADAMTS Metalloproteinases in Cancer

Publication date :

February 2008

Journal title :

Biochimie

ISSN :

0300-9084

eISSN :

1638-6183

Publisher :

Elsevier, Paris, France

Volume :

Issue :

Pages :

369-79

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 09 March 2009

Statistics

Number of views

324 (30 by ULiège)

Number of downloads

629 (17 by ULiège)

More statistics

Scopus citations^®

217

Scopus citations^®
without self-citations

207

OpenCitations

200

Bibliography

Butler C.A., Darragh K.M., Currie G.P., and Anderson W.J. Variation in lung cancer survival rates between countries: do differences in data reporting contribute?. Respir. Med 100 (2006) 1642-1646
Shibuya K., Inoue M., and Lopez A.D. Statistical modeling and projections of lung cancer mortality in 4 industrialized countries. Int. J. Cancer 117 (2005) 476-485
Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., and Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol 18 (2007) 581-592
Greenlee K.J., Werb Z., and Kheradmand F. Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted. Physiol. Rev. 87 (2007) 69-98
Handsley M.M., and Edwards D.R. Metalloproteinases and their inhibitors in tumor angiogenesis. Int. J. Cancer 115 (2005) 849-860
A. Noel, M. Jost, E. Maquoi, Matrix metalloproteinases at cancer tumor-host interface. Semin. Cell Dev. Biol, in press, doi:10.1016/j.semcdb.2007.05.011
Overall C.M., and Dean R.A. Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer. Cancer Metastasis Rev. 25 (2006) 69-75
Overall C.M., and Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 6 (2006) 227-239
Page-McCaw A., Ewald A.J., and Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 8 (2007) 221-233
Wolfsberg T.G., Primakoff P., Myles D.G., and White J.M. ADAM, a novel family of membrane proteins containing a disintegrin and metalloprotease domain: multipotential functions in cell-cell and cell-matrix interactions. J. Cell Biol. 131 (1995) 275-278
Blobel C.P. Metalloprotease-disintegrins: links to cell adhesion and cleavage of TNF alpha and Notch. Cell 90 (1997) 589-592
Zhang X.P., Kamata T., Yokoyama K., Puzon-McLaughlin W., and Takada Y. Specific interaction of the recombinant disintegrin-like domain of MDC-15 (metargidin, ADAM-15) with integrin alphavbeta3. J. Biol. Chem. 273 (1998) 7345-7350
Loechel F., Gilpin B.J., Engvall E., Albrechtsen R., and Wewer U.M. Human ADAM 12 (meltrin alpha) is an active metalloprotease. J. Biol. Chem. 273 (1998) 16993-16997
Black R.A., and White J.M. ADAMs: focus on the protease domain. Curr. Opin. Cell Biol. 10 (1998) 654-659
Eto K., Huet C., Tarui T., et al. Functional classification of ADAMs based on a conserved motif for binding to integrin alpha 9beta 1: implications for sperm-egg binding and other cell interactions. J. Biol. Chem. 277 (2002) 17804-17810
Reiss K., Ludwig A., and Saftig P. Breaking up the tie: disintegrin-like metalloproteinases as regulators of cell migration in inflammation and invasion. Pharmacol. Ther 111 (2006) 985-1006
Takeda S., Igarashi T., Mori H., and Araki S. Crystal structures of VAP1 reveal ADAMs' MDC domain architecture and its unique C-shaped scaffold. EMBO J 25 (2006) 2388-2396
Huovila A.P., Almeida E.A., and White J.M. ADAMs and cell fusion. Curr. Opin. Cell Biol. 8 (1996) 692-699
Stone A.L., Kroeger M., and Sang Q.X. Structure-function analysis of the ADAM family of disintegrin-like and metalloproteinase-containing proteins (review). J. Protein Chem. 18 (1999) 447-465
Seals D.F., and Courtneidge S.A. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 17 (2003) 7-30
Apte S.S. A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motifs: the ADAMTS family. Int. J. Biochem. Cell Biol. 36 (2004) 981-985
Cal S., Obaya A.J., Llamazares M., Garabaya C., Quesada V., and Lopez-Otin C. Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains. Gene 283 (2002) 49-62
Porter S., Clark I.M., Kevorkian L., and Edwards D.R. The ADAMTS metalloproteinases. Biochem. J. 386 (2005) 15-27
Kaushal G.P., and Shah S.V. The new kids on the block: ADAMTSs, potentially multifunctional metalloproteinases of the ADAM family. J. Clin. Invest 105 (2000) 1335-1337
Tang B.L., and Hong W. ADAMTS: a novel family of proteases with an ADAM protease domain and thrombospondin 1 repeats. FEBS Lett. 445 (1999) 223-225
Amour A., Knight C.G., Webster A., et al. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett. 473 (2000) 275-279
Kashiwagi M., Tortorella M., Nagase H., and Brew K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J. Biol. Chem. 276 (2001) 12501-12504
Murphy G., Knauper V., Lee M.H., et al. Role of TIMPs (tissue inhibitors of metalloproteinases) in pericellular proteolysis: the specificity is in the detail. Biochem. Soc. Symp 70 (2003) 65-80
Nagase H., and Brew K. Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors. Biochem. Soc. Symp 70 (2003) 201-212
Amour A., Knight C.G., English W.R., et al. The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Lett. 524 (2002) 154-158
Wayne G.J., Deng S.J., Amour A., et al. TIMP-3 inhibition of ADAMTS-4 (Aggrecanase-1) is regulated by interactions between aggrecan and the C-terminal domain of ADAMTS-4. J. Biol. Chem. 282 (2007) 20991-20998
Yuan R., Primakoff P., and Myles D.G. A role for the disintegrin domain of cyritestin, a sperm surface protein belonging to the ADAM family, in mouse sperm-egg plasma membrane adhesion and fusion. J. Cell Biol. 137 (1997) 105-112
Yang P., Baker K.A., and Hagg T. The ADAMs family: coordinators of nervous system development, plasticity and repair. Prog. Neurobiol. 79 (2006) 73-94
Kawaguchi N., Xu X., Tajima R., et al. ADAM 12 protease induces adipogenesis in transgenic mice. Am. J. Pathol 160 (2002) 1895-1903
Masaki M., Kurisaki T., Shirakawa K., and Sehara-Fujisawa A. Role of meltrin {alpha} (ADAM12) in obesity induced by high- fat diet. Endocrinology 146 (2005) 1752-1763
Gilpin B.J., Loechel F., Mattei M.G., Engvall E., Albrechtsen R., and Wewer U.M. A novel, secreted form of human ADAM 12 (meltrin alpha) provokes myogenesis in vivo. J. Biol. Chem. 273 (1998) 157-166
Black R.A., Rauch C.T., Kozlosky C.J., et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385 (1997) 729-733
Moss M.L., Jin S.L., Milla M.E., et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 385 (1997) 733-736
Sahin U., Weskamp G., Kelly K., et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J. Cell Biol. 164 (2004) 769-779
Hartmann D., de Strooper B., Serneels L., et al. The disintegrin/metalloprotease ADAM 10 is essential for notch signalling but not for alpha-secretase activity in fibroblasts. Hum. Mol. Genet. 11 (2002) 2615-2624
Qi H., Rand M.D., Wu X., et al. Processing of the notch ligand delta by the metalloprotease Kuzbanian. Science 283 (1999) 91-94
Taylor K.L., Henderson A.M., and Hughes C.C. Notch activation during endothelial cell network formation in vitro targets the basic HLH transcription factor HESR-1 and downregulates VEGFR-2/KDR expression. Microvasc. Res. 64 (2002) 372-383
Jones G.C. ADAMTS proteinases: potential therapeutic targets?. Curr. Pharm. Biotechnol 7 (2006) 25-31
Kern C.B., Twal W.O., Mjaatvedt C.H., et al. Proteolytic cleavage of versican during cardiac cushion morphogenesis. Dev. Dyn 235 (2006) 2238-2247
Manso A.M., Elsherif L., Kang S.M., and Ross R.S. Integrins, membrane-type matrix metalloproteinases and ADAMs: potential implications for cardiac remodeling. Cardiovasc. Res. 69 (2006) 574-584
Levy G.G., Nichols W.C., Lian E.C., et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413 (2001) 488-494
Brynskov J., Foegh P., Pedersen G., et al. Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut 51 (2002) 37-43
Foley S.C., Mogas A.K., Olivenstein R., et al. Increased expression of ADAM33 and ADAM8 with disease progression in asthma. J. Allergy Clin. Immunol 119 (2007) 863-871
Holgate S.T., Yang Y., Haitchi H.M., et al. The genetics of asthma: ADAM33 as an example of a susceptibility gene. Proc. Am. Thorac. Soc. 3 (2006) 440-443
Van Eerdewegh P., Little R.D., Dupuis J., et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature 418 (2002) 426-430
King N.E., Zimmermann N., Pope S.M., et al. Expression and regulation of a disintegrin and metalloproteinase (ADAM) 8 in experimental asthma. Am. J. Respir. Cell Mol. Biol. 31 (2004) 257-265
Paulissen G., Rocks N., Quesada-Calvo F., et al. Expression of ADAMs and their inhibitors in sputum from patients with asthma. Mol. Med 12 (2006) 171-179
East C.J., Stanton H., Golub S.B., Rogerson F.M., and Fosang A.J. ADAMTS-5 deficiency does not block aggrecanolysis at preferred cleavage sites in the chondroitin sulfate-rich region of aggrecan. J. Biol. Chem. 282 (2007) 8632-8640
Koshy P.J., Lundy C.J., Rowan A.D., et al. The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction. Arthritis Rheum 46 (2002) 961-967
Little C.B., Meeker C.T., Golub S.B., et al. Blocking aggrecanase cleavage in the aggrecan interglobular domain abrogates cartilage erosion and promotes cartilage repair. J. Clin. Invest 117 (2007) 1627-1636
Stanton H., Rogerson F.M., East C.J., et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 434 (2005) 648-652
Gendron C., Kashiwagi M., Lim N.H., et al. Proteolytic activities of human ADAMTS-5: comparative studies with ADAMTS-4. J. Biol. Chem. 282 (2007) 18294-18306
Al Fakhri N., Wilhelm J., Hahn M., et al. Increased expression of disintegrin-metalloproteinases ADAM-15 and ADAM-9 following upregulation of integrins alpha5beta1 and alphavbeta3 in atherosclerosis. J. Cell Biochem 89 (2003) 808-823
Cauwe B., Steen P.E., and Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit. Rev. Biochem. Mol. Biol. 42 (2007) 113-185
Sanderson M.P., Dempsey P.J., and Dunbar A.J. Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors. Growth Factors 24 (2006) 121-136
Iba K., Albrechtsen R., Gilpin B.J., Loechel F., and Wewer U.M. Cysteine-rich domain of human ADAM 12 (meltrin alpha) supports tumor cell adhesion. Am. J. Pathol 154 (1999) 1489-1501
Iba K., Albrechtsen R., Gilpin B., et al. The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to beta1 integrin-dependent cell spreading. J. Cell Biol. 149 (2000) 1143-1156
Wild-Bode C., Fellerer K., Kugler J., Haass C., and Capell A. A basolateral sorting signal directs ADAM10 to adherens junctions and is required for its function in cell migration. J. Biol. Chem. 281 (2006) 23824-23829
Frohlich C., Albrechtsen R., Dyrskjot L., Rudkjaer L., Orntoft T.F., and Wewer U.M. Molecular profiling of ADAM12 in human bladder cancer. Clin. Cancer Res. 12 (2006) 7359-7368
Ishikawa N., Daigo Y., Yasui W., et al. ADAM8 as a novel serological and histochemical marker for lung cancer. Clin. Cancer Res. 10 (2004) 8363-8370
Porter S., Scott S.D., Sassoon E.M., et al. Dysregulated expression of adamalysin-thrombospondin genes in human breast carcinoma. Clin. Cancer Res. 10 (2004) 2429-2440
Sung S.Y., Kubo H., Shigemura K., et al. Oxidative stress induces ADAM9 protein expression in human prostate cancer cells. Cancer Res. 66 (2006) 9519-9526
Bevitt D.J., Li Z., Lindrop J.L., Barker M.D., Clarke M.P., and McKie N. Analysis of full length ADAMTS6 transcript reveals alternative splicing and a role for the 5′ untranslated region in translational control. Gene 359 (2005) 99-110
Cerretti D.P., DuBose R.F., Black R.A., and Nelson N. Isolation of two novel metalloproteinase-disintegrin (ADAM) cDNAs that show testis-specific gene expression. Biochem. Biophys. Res. Commun 263 (1999) 810-815
Hotoda N., Koike H., Sasagawa N., and Ishiura S. A secreted form of human ADAM9 has an alpha-secretase activity for APP. Biochem. Biophys. Res. Commun 293 (2002) 800-805
Howard L., Maciewicz R.A., and Blobel C.P. Cloning and characterization of ADAM28: evidence for autocatalytic pro-domain removal and for cell surface localization of mature ADAM28. Biochem. J. 348 Pt 1 (2000) 21-27
Katagiri T., Harada Y., Emi M., and Nakamura Y. Human metalloprotease/disintegrin-like (MDC) gene: exon-intron organization and alternative splicing. Cytogenet. Cell Genet. 68 (1995) 39-44
Kurisaki T., Wakatsuki S., and Sehara-Fujisawa A. Meltrin beta mini, a new ADAM19 isoform lacking metalloprotease and disintegrin domains, induces morphological changes in neuronal cells. FEBS Lett. 532 (2002) 419-422
Ortiz R.M., Karkkainen I., and Huovila A.P. Aberrant alternative exon use and increased copy number of human metalloprotease-disintegrin ADAM15 gene in breast cancer cells. Genes Chromosomes Cancer 41 (2004) 366-378
Sagane K., Ohya Y., Hasegawa Y., and Tanaka I. Metalloproteinase-like, disintegrin-like, cysteine-rich proteins MDC2 and MDC3: novel human cellular disintegrins highly expressed in the brain. Biochem. J. 334 Pt 1 (1998) 93-98
Wainwright S.D., Bondeson J., and Hughes C.E. An alternative spliced transcript of ADAMTS4 is present in human synovium from OA patients. Matrix Biol. 25 (2006) 317-320
Yavari R., Adida C., Bray-Ward P., Brines M., and Xu T. Human metalloprotease-disintegrin Kuzbanian regulates sympathoadrenal cell fate in development and neoplasia. Hum. Mol. Genet. 7 (1998) 1161-1167
Liu Y.J., Xu Y., and Yu Q. Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively. Oncogene 25 (2006) 2452-2467
Rodriguez-Manzaneque J.C., Milchanowski A.B., Dufour E.K., Leduc R., and Iruela-Arispe M.L. Characterization of METH-1/ADAMTS1 processing reveals two distinct active forms. J. Biol. Chem. 275 (2000) 33471-33479
Blobel C.P. ADAMs: key components in EGFR signalling and development. Nat. Rev. Mol. Cell Biol. 6 (2005) 32-43
Schafer B., Marg B., Gschwind A., and Ullrich A. Distinct ADAM metalloproteinases regulate G protein-coupled receptor-induced cell proliferation and survival. J. Biol. Chem. 279 (2004) 47929-47938
Gschwind A., Hart S., Fischer O.M., and Ullrich A. TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO J 22 (2003) 2411-2421
Zhang Q., Thomas S.M., Lui V.W., et al. Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc. Natl. Acad. Sci. USA 103 (2006) 6901-6906
Ongusaha P.P., Kwak J.C., Zwible A.J., et al. HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer Res. 64 (2004) 5283-5290
Horiuchi K., Le Gall S., Schulte M., et al. Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. Mol. Biol. Cell 18 (2007) 176-188
Sahin U., and Blobel C.P. Ectodomain shedding of the EGF-receptor ligand epigen is mediated by ADAM17. FEBS Lett. 581 (2007) 41-44
Santiago-Josefat B., Esselens C., Bech-Serra J.J., and Arribas J. Post-transcriptional up-regulation of ADAM17 upon epidermal growth factor receptor activation and in breast tumors. J. Biol. Chem. 282 (2007) 8325-8331
Ito K., Okamoto I., Araki N., et al. Calcium influx triggers the sequential proteolysis of extracellular and cytoplasmic domains of E-cadherin, leading to loss of beta-catenin from cell-cell contacts. Oncogene 18 (1999) 7080-7090
Maretzky T., Reiss K., Ludwig A., et al. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proc. Natl. Acad. Sci. USA 102 (2005) 9182-9187
Shtutman M., Zhurinsky J., Simcha I., et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. USA 96 (1999) 5522-5527
Kveiborg M., Frohlich C., Albrechtsen R., et al. A role for ADAM12 in breast tumor progression and stromal cell apoptosis. Cancer Res. 65 (2005) 4754-4761
Fridman J.S., Caulder E., Hansbury M., et al. Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clin. Cancer Res. 13 (2007) 1892-1902
Bajou K., Maillard C., Jost M., et al. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 23 (2004) 6986-6990
Fidler I.J., and Ellis L.M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79 (1994) 185-188
Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
Jost M., Folgueras A.R., Frerart F., et al. Earlier onset of tumoral angiogenesis in matrix metalloproteinase-19-deficient mice. Cancer Res. 66 (2006) 5234-5241
Noel A., Maillard C., Rocks N., et al. Membrane associated proteases and their inhibitors in tumour angiogenesis. J. Clin. Pathol 57 (2004) 577-584
Roy R., Zhang B., and Moses M.A. Making the cut: protease-mediated regulation of angiogenesis. Exp. Cell Res. 312 (2006) 608-622
Vazquez F., Hastings G., Ortega M.A., et al. METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J. Biol. Chem. 274 (1999) 23349-23357
Iruela-Arispe M.L., Lombardo M., Krutzsch H.C., Lawler J., and Roberts D.D. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation 100 (1999) 1423-1431
Lawler J. The functions of thrombospondin-1 and-2. Curr. Opin. Cell Biol. 12 (2000) 634-640
Luque A., Carpizo D.R., and Iruela-Arispe M.L. ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. J. Biol. Chem. 278 (2003) 23656-23665
Kuno K., Bannai K., Hakozaki M., Matsushima K., and Hirose K. The carboxyl-terminal half region of ADAMTS-1 suppresses both tumorigenicity and experimental tumor metastatic potential. Biochem. Biophys. Res. Commun 319 (2004) 1327-1333
Herren B., Raines E.W., and Ross R. Expression of a disintegrin-like protein in cultured human vascular cells and in vivo. FASEB J 11 (1997) 173-180
Trochon-Joseph V., Martel-Renoir D., Mir L.M., et al. Evidence of antiangiogenic and antimetastatic activities of the recombinant disintegrin domain of metargidin. Cancer Res. 64 (2004) 2062-2069
Horiuchi K., Weskamp G., Lum L., et al. Potential role for ADAM15 in pathological neovascularization in mice. Mol. Cell Biol. 23 (2003) 5614-5624
Beck V., Herold H., Benge A., et al. ADAM15 decreases integrin alphavbeta3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion. Int. J. Biochem. Cell Biol. 37 (2005) 590-603
Lemjabbar H., Li D., Gallup M., Sidhu S., Drori E., and Basbaum C. Tobacco smoke-induced lung cell proliferation mediated by tumor necrosis factor alpha-converting enzyme and amphiregulin. J. Biol. Chem. 278 (2003) 26202-26207
Zhou B.B., Peyton M., He B., et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 10 (2006) 39-50
Shintani Y., Higashiyama S., Ohta M., et al. Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis. Cancer Res. 64 (2004) 4190-4196
Rocks N., Paulissen G., Quesada C.F., et al. Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC). Br. J. Cancer 94 (2006) 724-730
Mochizuki S., Shimoda M., Shiomi T., Fujii Y., and Okada Y. ADAM28 is activated by MMP-7 (matrilysin-1) and cleaves insulin-like growth factor binding protein-3. Biochem. Biophys. Res. Commun 315 (2004) 79-84
Ohtsuka T., Shiomi T., Shimoda M., et al. ADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis. Int. J. Cancer 118 (2006) 263-273
Schutz A., Hartig W., Wobus M., Grosche J., Wittekind C., and Aust G. Expression of ADAM15 in lung carcinomas. Virchows Arch. 446 (2005) 421-429
Dunn J.R., Panutsopulos D., Shaw M.W., et al. METH-2 silencing and promoter hypermethylation in NSCLC. Br. J. Cancer 91 (2004) 1149-1154
Harada T., Nishie A., Torigoe K., et al. The specific expression of three novel splice variant forms of human metalloprotease-like disintegrin-like cysteine-rich protein 2 gene in brain tissues and gliomas. Jpn. J. Cancer Res. 91 (2000) 1001-1006
D'Abaco G.M., Ng K., Paradiso L., Godde N.J., Kaye A., and Novak U. ADAM22, expressed in normal brain but not in high-grade gliomas, inhibits cellular proliferation via the disintegrin domain. Neurosurgery 58 (2006) 179-186
Bohm M., Gerlach R., Beecken W.D., Scheuer T., Stier-Bruck I., and Scharrer I. ADAMTS-13 activity in patients with brain and prostate tumors is mildly reduced, but not correlated to stage of malignancy and metastasis. Thromb. Res. 111 (2003) 33-37
Dunn J.R., Reed J.E., du Plessis D.G., et al. Expression of ADAMTS-8, a secreted protease with antiangiogenic properties, is downregulated in brain tumours. Br. J. Cancer 94 (2006) 1186-1193
Held-Feindt J., Paredes E.B., Blomer U., et al. Matrix-degrading proteases ADAMTS4 and ADAMTS5 (disintegrins and metalloproteinases with thrombospondin motifs 4 and 5) are expressed in human glioblastomas. Int. J. Cancer 118 (2006) 55-61
Zheng X., Jiang F., Katakowski M., et al. Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness. Cancer Sci. 98 (2007) 674-684
Wildeboer D., Naus S., Amy Sang Q.X., Bartsch J.W., and Pagenstecher A. Metalloproteinase disintegrins ADAM8 and ADAM19 are highly regulated in human primary brain tumors and their expression levels and activities are associated with invasiveness. J. Neuropathol. Exp. Neurol 65 (2006) 516-527
Kodama T., Ikeda E., Okada A., et al. ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor. Am. J. Pathol 165 (2004) 1743-1753
Bertram J., Peacock J.W., Fazli L., et al. Loss of PTEN is associated with progression to androgen independence. Prostate 66 (2006) 895-902
Ichikawa T., Suzuki H., Ueda T., Komiya A., Imamoto T., and Kojima S. Hormone treatment for prostate cancer: current issues and future directions. Cancer Chemother. Pharmacol 56 Suppl. 1 (2005) 58-63
McCulloch D.R., Harvey M., and Herington A.C. The expression of the ADAMs proteases in prostate cancer cell lines and their regulation by dihydrotestosterone. Mol. Cell Endocrinol 167 (2000) 11-21
Shigemura K., Sung S.Y., Kubo H., et al. Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells. Prostate 67 (2007) 722-731
Fritzsche F.R., Jung M., Xu C., et al. ADAM8 expression in prostate cancer is associated with parameters of unfavorable prognosis. Virchows Arch. 449 (2006) 628-636
Koo B.H., Oh D., Chung S.Y., et al. Deficiency of von Willebrand factor-cleaving protease activity in the plasma of malignant patients. Thromb. Res. 105 (2002) 471-476
Oleksowicz L., Bhagwati N., and DeLeon-Fernandez M. Deficient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies. Cancer Res. 59 (1999) 2244-2250
Cross N.A., Chandrasekharan S., Jokonya N., et al. The expression and regulation of ADAMTS-1, -4, -5, -9, and -15, and TIMP-3 by TGFbeta1 in prostate cells: relevance to the accumulation of versican. Prostate 63 (2005) 269-275
Kuefer R., Day K.C., Kleer C.G., et al. ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease. Neoplasia 8 (2006) 319-329
Moss M.L., White J.M., Lambert M.H., and Andrews R.C. TACE and other ADAM proteases as targets for drug discovery. Drug Discov. Today 6 (2001) 417-426
McCulloch D.R., Akl P., Samaratunga H., Herington A.C., and Odorico D.M. Expression of the disintegrin metalloprotease, ADAM-10, in prostate cancer and its regulation by dihydrotestosterone, insulin-like growth factor I, and epidermal growth factor in the prostate cancer cell model LNCaP. Clin. Cancer Res. 10 (2004) 314-323
Theret N., Musso O., Turlin B., et al. Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology 34 (2001) 82-88
Le Pabic H., Bonnier D., Wewer U.M., et al. ADAM12 in human liver cancers: TGF-beta-regulated expression in stellate cells is associated with matrix remodeling. Hepatology 37 (2003) 1056-1066
Matsuo M., Sakurai H., Ueno Y., Ohtani O., and Saiki I. Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin alphav-mediated ADAM activity in hepatocellular carcinoma: a novel functional target for gefitinib. Cancer Sci. 97 (2006) 155-162
Murillo M.M., del Castillo G., Sanchez A., Fernandez M., and Fabregat I. Involvement of EGF receptor and c-Src in the survival signals induced by TGF-beta1 in hepatocytes. Oncogene 24 (2005) 4580-4587
Le Pabic H., L'Helgoualc'h A., Coutant A., et al. Involvement of the serine/threonine p70S6 kinase in TGF-beta1-induced ADAM12 expression in cultured human hepatic stellate cells. J. Hepatol 43 (2005) 1038-1044
Atfi A., Dumont E., Colland F., et al. The disintegrin and metalloproteinase ADAM12 contributes to TGF-{beta} signaling through interaction with the type II receptor. J. Cell Biol. 178 (2007) 201-208
Mazzocca A., Coppari R., De Franco R., et al. A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res. 65 (2005) 4728-4738
Borrell-Pages M., Rojo F., Albanell J., Baselga J., and Arribas J. TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J 22 (2003) 1114-1124
Roy R., Wewer U.M., Zurakowski D., Pories S.E., and Moses M.A. ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J. Biol. Chem. 279 (2004) 51323-51330
McGowan P.M., Ryan B.M., Hill A.D., McDermott E., O'Higgins N., and Duffy M.J. ADAM-17 expression in breast cancer correlates with variables of tumor progression. Clin. Cancer Res. 13 (2007) 2335-2343
Kenny P.A., and Bissell M.J. Targeting TACE-dependent EGFR ligand shedding in breast cancer. J. Clin. Invest 117 (2007) 337-345
Mitsui Y., Mochizuki S., Kodama T., et al. ADAM28 is overexpressed in human breast carcinomas: implications for carcinoma cell proliferation through cleavage of insulin-like growth factor binding protein-3. Cancer Res. 66 (2006) 9913-9920
O'Shea C., McKie N., Buggy Y., et al. Expression of ADAM-9 mRNA and protein in human breast cancer. Int. J. Cancer 105 (2003) 754-761
Sieuwerts A.M., Meijer-van Gelder M.E., Timmermans M., et al. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study. Clin. Cancer Res. 11 (2005) 7311-7321
Porter S., Span P.N., Sweep F.C., et al. ADAMTS8 and ADAMTS15 expression predicts survival in human breast carcinoma. Int. J. Cancer 118 (2006) 1241-1247
Carl-McGrath S., Lendeckel U., Ebert M., Roessner A., and Rocken C. The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int. J. Oncol 26 (2005) 17-24
Yoshimura T., Tomita T., Dixon M.F., Axon A.T., Robinson P.A., and Crabtree J.E. ADAMs (a disintegrin and metalloproteinase) messenger RNA expression in Helicobacter pylori-infected, normal, and neoplastic gastric mucosa. J. Infect. Dis 185 (2002) 332-340
Cox J.M., Clayton C.L., Tomita T., Wallace D.M., Robinson P.A., and Crabtree J.E. cDNA array analysis of cag pathogenicity island-associated Helicobacter pylori epithelial cell response genes. Infect. Immun 69 (2001) 6970-6980
Joh T., Kataoka H., Tanida S., et al. Helicobacter pylori-stimulated interleukin-8 (IL-8) promotes cell proliferation through transactivation of epidermal growth factor receptor (EGFR) by disintegrin and metalloproteinase (ADAM) activation. Dig. Dis. Sci. 50 (2005) 2081-2089
Blanchot-Jossic F., Jarry A., Masson D., et al. Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells. J. Pathol 207 (2005) 156-163
Hirao T., Nanba D., Tanaka M., et al. Overexpression of ADAM9 enhances growth factor-mediated recycling of E-cadherin in human colon cancer cell line HT29 cells. Exp. Cell Res. 312 (2006) 331-339
Lind G.E., Kleivi K., Meling G.I., et al. ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis. Cell Oncol 28 (2006) 259-272
Yamada D., Ohuchida K., Mizumoto K., et al. Increased expression of ADAM 9 and ADAM 15 mRNA in pancreatic cancer. Anticancer Res. 27 (2007) 793-799
Masui T., Hosotani R., Tsuji S., et al. Expression of METH-1 and METH-2 in pancreatic cancer. Clin. Cancer Res. 7 (2001) 3437-3443
Ringel J., Jesnowski R., Moniaux N., et al. Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-alpha converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma. Cancer Res. 66 (2006) 9045-9053